Back

Experts discuss several recent data updates in the treatment of myeloproliferative neoplasms (MPNs) and the impact on clinical practice.

Expert Insights Into the Management of MPNs

Episodes

Specialty:

All

Year:

All

EP. 1: An Overview of Myeloproliferative Neoplasms (MPNs)

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

June 26th 2023

Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.

EP. 2: Risk Assessment for Patients with Polycythemia Vera (PV)

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

June 26th 2023

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

EP. 3: Current Treatment Landscape for Patients With PV

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 3rd 2023

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

EP. 4: Selecting a Frontline Therapy for Patients With PV

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 3rd 2023

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

EP. 5: Ruxolitinib for the Management of PV

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 10th 2023

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

EP. 6: Ropeginterferon alfa-2b for the Treatment of PV

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 10th 2023

Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.

EP. 7: Reviewing the Types of Myelofibrosis

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 17th 2023

The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.

EP. 8: The Role of Transplant in the Treatment of Patients With MF

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 17th 2023

Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.

EP. 9: COMFORT-I and COMFORT-II Data Review

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 24th 2023

Jamile Shammo, MD, comments the currently approved treatment options for patients with myelofibrosis and review data from the COMFORT-I and COMFORT-II trials, which evaluates the use of ruxolitinib in MF.

EP. 10: Pacritinib and Fedratinib for the Treatment of MF

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 24th 2023

Raajit Rampal, MD, and Abdulraheem Yacoub, MD, review data on the use of pacritinib and fedratinib in patients with myelofibrosis.

EP. 11: Sequencing Therapies in Patients with MF

ByJamile Shammo, MD,Naveen Pemmaraju, MD,Raajit K. Rampal, MD, PhD,Abdulraheem Yacoub, MD

July 31st 2023

Dr Jamile Shammo discusses how to approach sequencing therapies in patients with myelofibrosis and Dr Raajit Rampal explains the potential of the JAK inhibitor momelotinib in the treatment of myelofibrosis.